Press Releases

Tubulis publishes article in Molecular Cancer Therapeutics on advantages of its proprietary P5/Tubutecan platform

We are further advancing our technologies!

Please see Tubulis’ recent publication in Molecular Cancer Therapeutics on how to leverage the unique properties of our P5 technology to generate cutting-edge Topo-I-based high DAR ADCs with minimal aggregation, mAb like PK of the ADC and highest linkage stability leading to unrivaled in vivo efficacy.

Contacts

For Tubulis
Dominik Schumacher,
CEO & Co-Founder
Phone: +49 175 800 5594
Email: contact@tubulis.com

Media Requests for Tubulis
Trophic Communications
Stephanie May or Marie Weickert
Phone: + 49 171 185 5682
Email: tubulis@trophic.eu

Share Article

More Press Releases

Tubulis Presents Preclinical Data for Solid Tumor Targeting ADC Candidates TUB-030 and TUB-040 Demonstrating Superior Efficacy Profile and a Wide Therapeutic Window at the AACR Annual Meeting 2024

Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline

Tubulis to Present Preclinical Proof-of-Concept Data for Two Lead ADC Candidates Targeting Solid Tumors at the AACR Annual Meeting 2024